About Jay Flatley
Jay Flatley is a director at Rivian Automotive, Inc. / DE.
Form D filings name Jay Flatley as a chairman at Cellanome.
Jay Flatley reports to the SEC as a director or officer of 7 public companies, including Denali Therapeutics (DNLI), Zymergen (ZY) and Coherent (COHR).
Jay Flatley first appears on SEC filings in 2006.
Experience
This experience comes from Jay Flatley's profile and from SEC filings. For roles taken from filings, the years are when the filings name Jay Flatley in the role, so the role may have started earlier or lasted longer.
RD
Rivian Automotive, Inc. / DE
Director
2021 – 2026 · Public company (RIVN)
Cellanome, Inc.
Chairman
2023 – 2026 · Foster City, CA
Cellanome makes a live-cell analysis platform for biological researchers.
DI
Denali Therapeutics Inc.
Director
2017 – 2026 · Public company (DNLI)
ZI
Zymergen Inc.
Chairman and Acting CEO
2021 – 2022 · Public company (ZY)
CI
Coherent Inc.
Director
2011 – 2022 · Public company (COHR)
SI
Senti Biosciences, Inc.
Director
2021 · Public company (SNTI)
II
Illumina, Inc.
Chief Executive Officer and director
2006 – 2021 · Public company (ILMN)
JI
Juno Therapeutics, Inc.
Director
2017 – 2018 · Public company (JUNO)
Key Colleagues at Startups
The people Jay Flatley works with at each company, as listed on that company's latest Form D.
Cellanome, Inc. · Form D, Jun 22, 2026
MK
Mehdi Khodadad
Secretary
Mostafa Ronaghi
Cofounder, Executive Board Member
SP
Sandesh Patnam
Board Member
Omead Ostadan
CEO, Board Member
Rowan Chapman
Board Member